News from janssen pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 20, 2014, 16:05 ET

Janssen Pharmaceuticals and Diabetes Hands Foundation Encourage People with Type 2 Diabetes to Get Moving for National Diabetes Month

Janssen Pharmaceuticals, Inc. has teamed up with the Diabetes Hands Foundation to raise awareness about the importance of incorporating...

Sep 24, 2014, 16:30 ET

Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia

 Janssen Pharmaceuticals, Inc. announced the results of a first-of-its-kind study, The Impact of JANSSEN® CONNECT® Injection Centers...

Aug 25, 2014, 08:25 ET

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...

Aug 11, 2014, 18:18 ET
Aug 08, 2014, 19:15 ET
http://www.multivu.com/players/English/7288451-janssen-pharmaceuticals-fda-approved-invokamet-type-2-diabetes/gallery/image/2245cacc-b245-46fe-b426-f788a88626a7.HR.jpg

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

 Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET™, a fixed-dose therapy...

Jul 14, 2014, 08:00 ET

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies

 Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Jun 18, 2014, 08:30 ET

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for...

May 13, 2014, 09:00 ET

Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting...

May 06, 2014, 16:00 ET
May 05, 2014, 09:00 ET
Apr 23, 2014, 08:00 ET

Debbie Allen, So You Think You Can Dance, y Janssen Pharmaceuticals crearon T2 Dance Crew para que las personas con Diabetes tipo 2 se pusieran en movimiento

 La coreógrafa y actriz ganadora del Emmy® Debbie Allen, bailarines de la exitosa competencia de baile televisada So You Think...

Apr 23, 2014, 08:00 ET

Debbie Allen, So You Think You Can Dance and Janssen Pharmaceuticals Create the T2 Dance Crew to Get People with Type 2 Diabetes Moving

 Emmy®-award winning actress and choreographer Debbie Allen, dancers from the hit televised dance competition So You Think You Can Dance,...

Apr 22, 2014, 09:00 ET

Janssen Pharmaceuticals, Inc. Announces Key Research Presentations at 167th Annual Meeting of the American Psychiatric Association

 Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies,...

Mar 24, 2014, 08:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

 New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C...

Jan 08, 2014, 18:17 ET

Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars

Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety The Janssen Pharmaceutical Companies of Johnson...

Oct 08, 2013, 08:00 ET

Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline

 Janssen Pharmaceuticals, Inc. (Janssen) announced today the acquisition of the investigational compound GSK2336805, an NS5a replication...

Sep 20, 2013, 08:45 ET

Pooled Analysis Confirms XARELTO® has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE

Janssen Pharmaceuticals, Inc. (Janssen) announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing...

Apr 01, 2013, 17:55 ET

La FDA de EE. UU. aprueba INVOKANA™ (Canagliflozin) para el tratamiento de adultos con diabetes de tipo 2

Janssen Pharmaceuticals, Inc. anunció el viernes 29 de marzo que la Administración de Alimentos y Medicamentos de EE. UU....

Mar 29, 2013, 16:37 ET

U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes

Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the...

Mar 14, 2013, 08:30 ET

Doctors Agree Small Lifestyle Changes Can Improve Outcomes of Patients with Type 2 Diabetes, National Survey Finds

 A new, national survey revealed physicians feel type 2 diabetes patients could better manage their disease by appreciating the benefits of...